<DOC>
	<DOC>NCT02893618</DOC>
	<brief_summary>Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR, 1 of which is administered both with and without food.</brief_summary>
	<brief_title>A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)</brief_title>
	<detailed_description>Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR, 1 of which is administered both with and without food, with a 10 Day washout period between treatments. There will be 8 treatment sequences with 4 subjects randomized to each.</detailed_description>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>Ability to follow verbal and written instructions Informed consent form signed by the subject Completed screening within 7 days prior to dosing BMI between 18.5 and 35 kg/m2 Generally healthy fasting glucose less than or equal to 100 mg/dL HbA1c less than or equal to 6% Pregnancy or breast feeding absence of contraception administration of investigational drug within 1 month prior to screening anticipated requirement for prohibited medication (systemic corticosteroids or antidiabetic medications) allergic reaction to or significant intolerance of diazoxide, thiazides or sulfonamides known type 1 or type 2 diabetes mellitus congestive heart failure gastric bypass surgery history of drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>